Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 2/20 | 0.65 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.50 |
| ▸ | MAPT | P10636 | 3/20 | 0.50 |
| ▸ | HPGD | P15428 | 3/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.50 |
| ▸ | TSHR | P16473 | 2/20 | 0.50 |
| ▸ | RGS12 | O14924 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.50 |
| ▸ | APEX1 | P27695 | 1/20 | 0.50 |
| ▸ | THPO | P40225 | 1/20 | 0.50 |
| ▸ | BLM | P54132 | 1/20 | 0.50 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.50 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.50 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | RPA1 | P27694 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31048273 | 0.86 | PIK3CA (0.52) | CA2PIK3CAKDM4EMAPTTSHR | |
| SCHEMBL28638604 | 0.85 | PIK3CA (0.55) | CA2PIK3CAMAPTTSHRRPA1 | |
| SCHEMBL154404 | 0.85 | CA2 (0.59) | CA2PIK3CAKDM4EMAPTHPGD | |
| SCHEMBL30154466 | 0.85 | CA2 (0.59) | CA2PIK3CAKDM4EMAPTHPGD | |
| SCHEMBL21090110 | 0.85 | PIK3CA (0.58) | CA2PIK3CAKDM4EMAPTTSHR | |
| SCHEMBL28631085 | 0.84 | PIK3CA (0.51) | CA2PIK3CAMAPTTSHRRPA1 | |
| SCHEMBL11520973 | 0.83 | PIK3CA (0.56) | CA2PIK3CAKDM4EMAPTTSHR | |
| SCHEMBL1699595 | 0.83 | PIK3CA (0.56) | CA2PIK3CAKDM4EMAPTTSHR | |
| SCHEMBL3396522 | 0.83 | PIK3CA (0.56) | CA2PIK3CATSHRRPA1HDAC3 | |
| SCHEMBL27835202 | 0.83 | PIK3CA (0.56) | CA2PIK3CAKDM4EMAPTTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 168 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3114715-B1 | P-DOPING CROSS-LINKING OF ORGANIC HOLE TRANSPORTERS | SIEMENS AG (DE) | 2019-10-30 | — | — | EP | claimed |
| EP-3114715-A1 | P-DOPING CROSS-LINKING OF ORGANIC HOLE TRANSPORTERS | Siemens Aktiengesellschaft (DE) | 2017-01-11 | — | — | EP | claimed |
| US-12599587-B2 | Chlorinated tetralin compounds and pharmaceutical compositions | SPRINGWORKS THERAPEUTICS, INC. (US) | 2026-04-14 | — | — | US | disclosed |
| US-20260078091-A1 | Piperidinone Derivatives as MDM2 Inhibitors for the Treatment of Cancer | AMGEN INC (US) | 2026-03-19 | — | — | US | disclosed |
| US-20260034099-A1 | CHLORINATED TETRALIN COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS | SPRINGWORKS THERAPEUTICS INC (US) | 2026-02-05 | — | — | US | disclosed |
| US-20250185502-A1 | ORGANIC OPTOELECTRONIC COMPONENT, ORGANIC FUNCTIONAL LAYER, AND METHOD FOR PRODUCING AN OPTOELECTRONIC COMPONENT | OSRAM OLED GMBH (DE) | 2025-06-05 | — | — | US | disclosed |
| US-12302747-B2 | Optoelectronic component, organic functional layer, and method for producing an optoelectronic component | OSRAM OLED GMBH (DE) | 2025-05-13 | — | — | US | disclosed |
| WO-2025064683-A1 | SMALL MOLECULE PROTEIN SYNTHESIS MODULATORS | Interdict Bio, Inc. (US) | 2025-03-27 | — | — | WO | disclosed |
| US-20250091989-A1 | SMALL MOLECULE PROTEIN SYNTHESIS MODULATORS | Interdict Bio, Inc. (US) | 2025-03-20 | — | — | US | disclosed |
| EP-4193399-B1 | ELECTRONIC DEVICE | MERCK PATENT GMBH (DE) | 2025-01-29 | — | — | EP | disclosed |
| US-20240300892-A1 | Piperidinone Derivatives as MDM2 Inhibitors for the Treatment of Cancer | AMGEN INC (US) | 2024-09-12 | — | — | US | disclosed |
| US-6545155-B2 | Useful for increasing insulin secretion in the treatment of type II diabetes | HOFFMANN-LA ROCHE INC. | 2003-04-08 | — | — | US | disclosed |
| US-6448399-B1 | 3-CYCLOALKYL- OR PROPYL-2-(3,4-DIHALOPHENYL)-N-QUINOLINYL-, QUINAZOLINYL-, OR QUINOXOLINYL-PROPIONAMIDE. | HOFFMANN-LA ROCHE INC. | 2002-09-10 | — | — | US | disclosed |
| US-6441184-B1 | SUCH AS N-BENZOOXAZOL-2-YL-3-CYCLOPENTYL-2-(4-METHANESULFONYL -PHENYL)-PROPIONAMIDE FOR INCREASING INSULIN SECRETION IN THE TREATMENT OF TYPE II DIABETES | HOFFMANN-LA ROCHE INC. | 2002-08-27 | — | — | US | disclosed |
| US-20020111372-A1 | FUSED HETEROAROMATIC GLUCOKINASE ACTIVATORS | CORBETT WENDY L (US) | 2002-08-15 | — | — | US | disclosed |
| US-6433188-B1 | ANTIDIABETIC AGENTS | CORBETT WENDY LEA (US) | 2002-08-13 | — | — | US | disclosed |
| US-20020107396-A1 | FUSED HETEROAROMATIC GLUCOKINASE ACTIVATORS | CORBETT WENDY LEA (US) | 2002-08-08 | — | — | US | disclosed |
| US-20020103199-A1 | Fused heteroaromatic glucokinase activators | CORBETT WENDY LEA (US) | 2002-08-01 | — | — | US | disclosed |
| US-20020103241-A1 | FUSED HETEROAROMATIC GLUCOKINASE ACTIVATORS | CORBETT WENDY L (US) | 2002-08-01 | — | — | US | disclosed |
| WO-2002046173-A1 | FUSED HETEROAROMATIC GLUCOKINASE ACTIVATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2002-06-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020111372-A1 | FUSED HETEROAROMATIC GLUCOKINASE ACTIVATORS | GCKR, GCK, GPR119 | CA2 1799/4885PIK3CA 1981/4885KDM4E 4010/4885 |
| US-20240300892-A1 | Piperidinone Derivatives as MDM2 Inhibitors for the Treatment of Cancer | MDM2, TP53, CDKN1A | CA2 3641/4885PIK3CA 99/4885KDM4E 734/4885 |
| US-20250091989-A1 | SMALL MOLECULE PROTEIN SYNTHESIS MODULATORS | MYC, KRAS, NRAS | CA2 3954/4885PIK3CA 1058/4885KDM4E 2188/4885 |
| US-20020103199-A1 | Fused heteroaromatic glucokinase activators | GCKR, GCK, GPR119 | CA2 1799/4885PIK3CA 1981/4885KDM4E 4010/4885 |
| US-20260034099-A1 | CHLORINATED TETRALIN COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS | BACE1, BACE2, DSG1 | CA2 215/4885PIK3CA 660/4885KDM4E 411/4885 |
| US-20260078091-A1 | Piperidinone Derivatives as MDM2 Inhibitors for the Treatment of Cancer | TP53, HIF1AN, MDM2 | CA2 535/4885PIK3CA 1119/4885KDM4E 197/4885 |
| US-12599587-B2 | Chlorinated tetralin compounds and pharmaceutical compositions | CLIC1, CLCN2, CSNK1D | CA2 693/4885PIK3CA 1657/4885KDM4E 1340/4885 |
| US-20020107396-A1 | FUSED HETEROAROMATIC GLUCOKINASE ACTIVATORS | GCKR, GCK, GPR119 | CA2 1799/4885PIK3CA 1981/4885KDM4E 4010/4885 |
| US-20020103241-A1 | FUSED HETEROAROMATIC GLUCOKINASE ACTIVATORS | GCKR, GCK, GPR119 | CA2 1799/4885PIK3CA 1981/4885KDM4E 4010/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.